UW Medicine
Mission Statement
At a Glance
1
Educational Resources Posted
5
Consortium News Stories Posted
5
Events Posted
0
Opportunities Posted
356
Publications citing CTSA Program Grant
50
Users from Hub Registered
UL1 Award
KL2 Award
TL1 Award
UL1
UL1 Director
UL1 Administrator
,Education
KL2 Director
KL2 Administrator
TL1 Administrator
Communications
Communications Representative
Enterprise Committees
Integration Across Lifespan Voting Member
Informatics Voting Member
Collaboration and Engagement Voting Member
Common Metrics
Primary CM Contact
SaraKimResearch Professor, Associate Dean for Educational Quality Improvement
AndreaLazarusAssociate Vice President for Health Sciences, Washington State University
HilaireThompsonProfessor; Assistant Vice Provost Office of Academic Personnel
Consortium News
Amy Lasek, a former UIC Center for Clinical and Translational Science pilot grant awardee (2018-2020) and researcher at UIC’s Center for Alcohol Research in Epigenetics, was published in the journal Translational Psychiatry. The study, “Transcriptomics identifies STAT3 as a key regulator of hippocampal gene expression and anhedonia during withdrawal from chronic alcohol exposure,” builds on her
Storytelling is one of the most effective ways to share our experiences and impart meaning onto our world. Through stories, we can connect with others in different levels, learn something new or feel inspired to explore new ideas. At the Institute of Translational Health Sciences (ITHS) we have an opportunity to do this by sharing our own stories of innovation, successes, research, new projects
Summary: Stakeholder engagement can play an important role in increasing public trust and the understanding of scientific research and its impact. Frameworks for stakeholder identification exist, but these frameworks may not apply well to basic science and early stage translational research. Methods: Four Clinical and Translational Science Award (CTSA) hubs led six focus groups and two semi
Educational Content
Events
University of Washington’s Institute of Translational Health Sciences is hosting Travis Kinder from the NCATS Intramural Research Program through the NIH Clinical and Translational Science Award (CTSA) Visiting Scholars Program on April 16 at 12pm PST. This program is designed to connect individuals with institutional KL2 awards from outside the UW with established UW faculty in their field as
The CTSA Center for Leading Innovation and Collaboration (CLIC) program has created the new NIH Clinical and Translational Science Award (CTSA) Visiting Scholars Program to help promote networking among KL2 Scholars. During the pandemic, KL2 Scholars are unable to visit other institutions or conferences to give presentations and network as they have in the past. This new program provides scholars
Poster Sessions
Many clinical questions have arisen with the COVID-19 pandemic, from who is at greatest risk for COVID-19 infection to adverse outcomes if infected to how COVID-19 has impacted healthcare utilization patterns. To help answer these questions, and many more, the National COVID Cohort Collaborative (N3C) has integrated real-world clinical observations from across the nation into a harmonized database
Since the first cases of COVID-19 arrived in the United States, various studies have reported that the SARS-CoV-2 virus is highly infectious and there has been a disproportionately greater negative impact upon communities already facing issues with racial disparities and challenges with social determinants of health (SDOH). Health systems, like UW Medicine, have provided SARS-CoV-2 testing to
Publications
Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation
Autologous, CCR5 gene-edited hematopoietic stem and progenitor cell (HSPC) transplantation is a promising strategy for achieving HIV remission. However, only a fraction of HSPCs can be edited ex vivo to provide protection against infection. To project the thresholds of CCR5-edition necessary for HIV
CMV viral load kinetics as surrogate endpoints after allogeneic transplantation
BACKGROUNDViral load (VL) surrogate endpoints transformed development of HIV and hepatitis C therapeutics. Surrogate endpoints for CMV-related morbidity and mortality could advance development of antiviral treatments. Although observational data support using CMV VL as a trial endpoint, randomized
F-domain valency determines outcome of signaling through the angiopoietin pathway
Angiopoietin 1 and 2 (Ang1 and Ang2) modulate angiogenesis and vascular homeostasis through engagement of their very similar F-domain modules with the Tie2 receptor tyrosine kinase on endothelial cells. Despite this similarity in the underlying receptor binding interaction, the two angiopoietins
Research and Operational Tools
In this time of unprecedented research need, the Institute of Translational Health Sciences is working relentlessly to provide research resources and help accelerate research that will help resolve the COVID-19 pandemic.